UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Diabetes, obesity & metabolism, 2009-06, Vol.11 (6), p.611-622

2009

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers

International journal of oncology, 2022-03, Vol.60 (3), p.1, Article 35

2022

Link zum Volltext

Verfügbarkeit prüfen

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Diabetes, obesity & metabolism, 2008-05, Vol.10 (5), p.376-386

2008

Link zum Volltext

Verfügbarkeit prüfen

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2564-2569

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Diabetes, obesity & metabolism, 2015-07, Vol.17 (7), p.630-638

2015

Link zum Volltext

Verfügbarkeit prüfen

Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer

Current opinion in urology, 2020-01, Vol.30 (1), p.98

2020

Link zum Volltext

Verfügbarkeit prüfen

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Diabetes, obesity & metabolism, 2014-10, Vol.16 (10), p.891-899

Davis, T. M. E.

2014

Link zum Volltext

Verfügbarkeit prüfen

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Diabetes, obesity & metabolism, 2016-02, Vol.18 (2), p.186-190

2016

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.523-532

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1513-1520

2017

Link zum Volltext

Verfügbarkeit prüfen

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.567-576

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Diabetes, obesity & metabolism, 2015-05, Vol.17 (5), p.487-494

2015

Link zum Volltext

Verfügbarkeit prüfen

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Diabetes, obesity & metabolism, 2016-12, Vol.18 (12), p.1253-1262

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of VX‑765 on the transcriptome profile of mice spinal cords with acute injury

Molecular medicine reports, 2020-07, Vol.22 (1), p.33-42

2020

Link zum Volltext

Verfügbarkeit prüfen

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1045-1050

2017

Link zum Volltext

Verfügbarkeit prüfen

Baseline differences in the SAVOR trial

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1202-1202

2015

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Diabetes, obesity & metabolism, 2012-06, Vol.14 (6), p.481-492

2012

Link zum Volltext

Verfügbarkeit prüfen

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2011-09, Vol.13 (9), p.850-858

2011

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin efficacy

Diabetes, obesity & metabolism, 2010-08, Vol.12 (8), p.734-734

Valiquette, G.

2010

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes

Cardiology in review, 2010-07, Vol.18 (4), p.213-217

2010

Link zum Volltext

Verfügbarkeit prüfen

Comparative effects of different antihypertensive treatments on progression of diabetic renal disease

Archives of internal medicine (1960), 1993-04, Vol.153 (8), p.973

1993

Link zum Volltext

Verfügbarkeit prüfen

Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report

Scandinavian journal of urology and nephrology. Supplement, 1984, Vol.79, p.103

1984

Link zum Volltext

Verfügbarkeit prüfen

How Should We Evaluate the Efficacy of Nutrition Support?

The Journal of Trauma: Injury, Infection, and Critical Care, 1997-02, Vol.42 (2), p.343-344

Souba, Wiley W.

1997

Link zum Volltext

Verfügbarkeit prüfen

Hemodynamic results of perorally administered converting enzyme inhibitors in congestive heart failure

Scandinavian journal of urology and nephrology. Supplement, 1984, Vol.79, p.129

1984

Link zum Volltext

Verfügbarkeit prüfen

Acute and subacute haemodynamic effects of enalapril. Non-invasive studies of a new converting enzyme inhibitor for antihypertensive treatment

Scandinavian journal of urology and nephrology. Supplement, 1984, Vol.79, p.81

1984

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Aktive Filter

KollektionSage Journals

Nur zeigenGeprüft (Peer-Review)

KollektionJournals@Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(28)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(32)
Dipeptides - Therapeutic Use
(31)
Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Adamantane - Analogs & Derivatives
(20)
Diabetes Mellitus, Type 2 - Drug Therapy
(20)
Male
(20)
Endocrinology & Metabolism
(19)
Female
(19)
Middle Aged
(18)
Adamantane - Therapeutic Use
(17)
Adult
(15)
Aged
(15)
Diabetes
(15)
Treatment Outcome
(15)
Dipeptidyl-Peptidase Iv Inhibitors - Therapeutic Use
(14)
Diabetes Mellitus
(12)
Double-Blind Method
(12)
Type 2 Diabetes
(10)
Hypoglycemic Agents - Therapeutic Use
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Effect of VX‑765 on the transcriptome profile of mice spinal cords with acute injury

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Baseline differences in the SAVOR trial

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Saxagliptin efficacy

Saxagliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes

Comparative effects of different antihypertensive treatments on progression of diabetic renal disease

Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report

How Should We Evaluate the Efficacy of Nutrition Support?

Hemodynamic results of perorally administered converting enzyme inhibitors in congestive heart failure

Acute and subacute haemodynamic effects of enalapril. Non-invasive studies of a new converting enzyme inhibitor for antihypertensive treatment

Aktive Filter

Suchergebnisse filtern